Please log in
to access more information

loading...

User name and Password not recognised

Home Page > News > BIOM’UP GRANTED FDA APPROVAL FOR ITS HEMOBLAST™ BELLOWS LAPAROSCOPIC APPLICATOR

BIOM’UP GRANTED FDA APPROVAL FOR ITS HEMOBLAST™ BELLOWS LAPAROSCOPIC APPLICATOR

Saint-Priest, France, January 22, 2019, 8:00 am (CET) – Biom’up (the “Company”), specializing in surgical hemostasis, has announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for its HEMOBLAST Bellows Laparoscopic Applicator for all minimally-invasive procedures. Biom’up submitted the premarket approval (PMA) supplement to the FDA in July, 2018. The FDA completed its response within the standard 180 days, for this type of supplement, applicable when no challenge is raised, demonstrating the quality of the Company’s regulatory work.

» Read and download the press release